| |
#23709 07-09-2007 03:19 PM | Joined: Mar 2002 Posts: 4,912 Likes: 52 OCF Founder Patient Advocate (old timer, 2000 posts) |  OCF Founder Patient Advocate (old timer, 2000 posts)
Joined: Mar 2002 Posts: 4,912 Likes: 52 | Erbitux is a monoclonal antibody. It is seldom used as a monotherapy since it does not directly kill malignant cells. It blocks a protein messenger that tells the malignant cells to duplicate, buying time for other chemo or rad to do the heavy lifting. When used as a monotherapy it is a time buyer primarily. See http://www.oralcancerfoundation.org/treatment/targeted_therapies.htm
Brian, stage 4 oral cancer survivor. OCF Founder and Director. The first responsibility of a leader is to define reality. The last is to say thank you. In between, the leader is a servant.
| | |
| Forums23 Topics18,170 Posts196,930 Members13,105 | | Most Online458
Jan 16th, 2020 | | |
|
| |
